All In Biotech

Drug Trial Radar · NCT06515990

A Study of DM005 in Patients With Advanced Solid Tumors

A Phase I/IIa, Multicenter, Open-label, First-in-human, Dose Escalation and Expansion Study of DM005 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

208

Planned (sponsor's estimate)

Start

Oct 31, 2024

Primary completion

Mar 2027

Study completion Sep 2027

Sponsor

Sponsor type
Industry
First posted
Jul 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM005 for patients with the advanced solid tumors. DM005 is an experimental drug which is not approved by health authorities for the treatment of advanced solid tumors. For each participant, there will be a screening period of up to 28 days, a treatment period consisting of 21-day cycles, an end of treatment (EOT) Visit (+7 days), and a Follow-up Visit at 30 days (±7 days) after the EOT Visit. Participants with advanced solid malignant tumors will be treated with DM005 on Day 1 of each cycle (every 3 weeks, Q3W). An initial dose of DM005 will be infused intravenously (IV) into each participant for approximately 60 minutes (±10) on Cycle1 Day 1. If there is no infusion-related reaction (IRR) during or after the initial dose, with the Investigator's confirmation and supervision, the subsequent dosing of DM005 in the following cycles maybe infused IV for approximately 30 minutes ( ±5). A 21-day observation period (Cycle 1) will then occur, at the end of which all relevant safety data will be reviewed.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Squamous Cell Carcinoma of Head and Neck
  • Solid Carcinoma

Interventions

  • DM005Drug

    An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting Toxicities (DLTs) of DM005Time frame: 12 months
  2. Maximum tolerated dose (MTD) for DM005Time frame: 12 months

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Henry Ford Cancer Institute

    Detroit, Michigan · Recruiting

  • Sarah Cannon Research Institute at Mary Crowley

    Dallas, Texas · Recruiting

  • NEXT Oncology Virginia

    Fairfax, Virginia · Recruiting

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia · Recruiting

  • Macquarie University Hospital

    North Ryde, New South Wales, Australia · Recruiting

  • ICON Cancer Center

    South Brisbane, Queensland, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.